Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on eastern cooperative oncology group clinical trials

Journal of Thoracic Oncology

Volumn 8, Issue 9, 2013, Pages 1121-1127

  Dahlberg, Suzanne E ^a   Schiller, Joan H ^b   Bonomi, Philip B ^c   Sandler, Alan B ^d   Brahmer, Julie R ^e   Ramalingam, Suresh S ^f   Johnson, David H ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f EMORY UNIVERSITY   (United States)

Author keywords

Advanced disease; Bevacizumab; Body mass index; Chemotherapy; First line therapy; Non smallcell lung cancer; Obesity; Phase III; Weight

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OBESITY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UNDERWEIGHT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OBESITY; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84883402702     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31829cf942     Document Type: Article

References (44)

1. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-497.
2. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-79.
3. Halabi S, Ou SS, Vogelzang NJ, Small EJ. Inverse correlation between body mass index and clinical outcomes in men with advanced castrationrecurrent prostate cancer. Cancer 2007;110:1478-1484.
4. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-591.
5. Renehan AG, Soerjomataram I, Leitzmann MF. Interpreting the epidemiological evidence linking obesity and cancer: a framework for population-attributable risk estimations in Europe. Eur J Cancer 2010;46: 2581-2592.
6. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-578.
7. Smith L, Brinton LA, Spitz MR, et al. Body mass index and risk of lung cancer among never, former, and current smokers. J Natl Cancer Inst 2012;104:778-789.
8. Andreotti G, Hou L, Beane Freeman LE, et al. Body mass index, agricultural pesticide use, and cancer incidence in the Agricultural Health Study cohort. Cancer Causes Control 2010;21:1759-1775.
9. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638.
10. Henley SJ, Flanders WD, Manatunga A, Thun MJ. Leanness and lung cancer risk: fact or artifact? Epidemiol 2002;13:268-276.
11. Kabat GC, Kim M, Hunt JR, Chlebowski RT, Rohan TE. Body mass index and waist circumference in relation to lung cancer risk in the Women's Health Initiative. Am J Epidemiol 2008;168:158-169.
12. Kabat GC, Miller AB, Rohan TE. Body mass index and lung cancer risk in women. Epidemiol 2007;18:607-612.
13. Knekt P, Heliövaara M, Rissanen A, et al. Leanness and lung-cancer risk. Int J Cancer 1991;49:208-213.
14. Leung CC, Lam TH, Yew WW, Chan WM, Law WS, Tam CM. Lower lung cancer mortality in obesity. Int J Epidemiol 2011;40:174-182.
15. Olson JE, Yang P, Schmitz K, Vierkant RA, Cerhan JR, Sellers TA. Differential association of body mass index and fat distribution with three major histologic types of lung cancer: evidence from a cohort of older women. Am J Epidemiol 2002;156:606-615.
16. Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni JF Jr. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 2006;17:901-909.
17. Tsai SP, Donnelly RP, Wendt JK. Obesity and mortality in a prospective study of a middle-aged industrial population. J Occup Environ Med 2006;48:22-27.
18. Yang L, Yang G, Zhou M, et al. Body mass index and mortality from lung cancer in smokers and nonsmokers: a nationally representative prospective study of 220,000 men in China. Int J Cancer 2009;125:2136-2143.
19. Yang R, Cheung MC, Pedroso FE, Byrne MM, Koniaris LG, Zimmers TA. Obesity and weight loss at presentation of lung cancer are associated with opposite effects on survival. J Surg Res 2011;170:e75-e83.
20. Carson KR, Bartlett NL, McDonald JR, et al. Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J Clin Oncol 2012;30:3217-3222.
21. Waalkes S, Merseburger AS, Kramer MW, et al. Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer. Cancer Causes Control 2010;21:1905-1910.
22. Sparano JA, Wang M, Zhao F, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 2012;118:5937-5946.
23. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623-631.
24. Schiller JH, Harrington D, Belani CP, et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer. N Engl J Med 2002;346:92-98.
25. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958.
27. Cox DR, Oates D. Regression models and life tables. J Royal Stat Soc B34:187-220, 1972.
28. Klabfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: Wiley; 1980.
29. World Health Organization. Global database on body mass index. Available at: http://apps.who.int/bmi/index.jspintroPage=intro-3.html Accessed November 1, 2012.
30. Grambsch P and Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biom 1994;81:515-26.
31. Schoenfeld D. Chi-squared goodness of fit tests for the proportional hazards regression model. Biom 1980;67:145-53.
32. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biom 1982;69:239-241.
33. Girnun GD, Naseri E, Vafai SB, et al. Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 2007;11: 395-406.
34. Wu N, Gu C, Gu H, Hu H, Han Y, Li Q. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma 2011;58:482-490.
35. Shackelford DB, Abt E, Gerken L, et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013;23:143-158.
36. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncol 2002;63:317-332.
37. O'Brien JM Jr, Phillips GS, Ali NA, Lucarelli M, Marsh CB, Lemeshow S. Body mass index is independently associated with hospital mortality in mechanically ventilated adults with acute lung injury. Crit Care Med 2006;34:738-744.
38. Wurzinger B, Dünser MW, Wohlmuth C, et al. The association between body-mass index and patient outcome in septic shock: a retrospective cohort study. Wien Klin Wochenschr 2010;122:31-36.
39. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009;53: 1925-1932.
40. Hanrahan CF, Golub JE, Mohapi L, et al. Body mass index and risk of tuberculosis and death. AIDS 2010;24:1501-1508.
41. Lavie CJ, De Schutter A, Patel DA, Milani RV. Body composition and fitness in the obesity paradox-Body mass index alone does not tell the whole story. Prev Med March 29, 2013. doi: 10.1016/j.ypmed.2013.03.010. [Epub ahead of print].
42. Sher DJ, Gielda BT, Liptay MJ, et al. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-smallcell lung cancer. Clin Lung Cancer December 20, 2012. doi: 10.1016/j. cllc.2012.10.009. [Epub ahead of print].
43. Gielda BT, Mehta P, Khan A, et al. Weight gain in advanced non-smallcell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys 2011;81:985-991.
44. Kutluk Cenik B, Sun H, Gerber DE. Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer. Lung Cancer 2013;80:326-332.